In the Matter Of Application For Leave To Be Added As Amicus Curiae by The Secretariat Of Joint United Nations Program On H... (Consolidated Constitutional Application 55 of 2023; Constitutional Application 60 of 2023) 2023 UGCC 111 (2023-1
The full judgment
Read the complete, verbatim text of this judgment.
AI-generated summary. This summary was generated by AI from the full text of the judgment. It may contain errors or omissions — always read the source judgment before relying on it.
Holding
The Court reaffirmed that admission of an amicus curiae is discretionary and governed by the tests in Rules 5, 7 and 8 of the Judicature (Amicus Curiae) Rules 2022. Despite the Attorney General's objection that UNAIDS held a public position against the Anti-Homosexuality Act, 2023, the Court admitted UNAIDS as amicus, finding that its documented global work on HIV/AIDS provided important information useful to deciding the consolidated petitions, subject to it filing a brief linking that expertise to the dispute. The pharmaceutical companies were refused: their materials were largely general corporate LGBTQ-support policies, did not amount to expert assistance, and, being profit-driven enterprises, failed the impartiality test.
Facts
Two applications sought leave to be joined as amicus curiae in consolidated constitutional petitions challenging the Anti-Homosexuality Act, 2023. In Application No. 55 of 2023, UNAIDS, a joint programme uniting eleven UN agencies in the global fight against HIV/AIDS, sought to address the Court on the Act's impact on efforts to curtail HIV/AIDS and on the right to health. In Application No. 60 of 2023, four pharmaceutical companies sought to present perspectives from the healthcare sector on access to health services for those affected by the Act. The Attorney General opposed both, contending the applicants harboured negative sentiments towards the Act and were neither neutral nor impartial, citing UNAIDS website publications urging Uganda not to enact the law and the companies' corporate policies supporting LGBTQ communities. UNAIDS's amicus brief did not connect its documented worldwide work to the matters before the Court, while the companies' materials were largely general corporate policies and their brief raised concerns about the Act's effect on their business operations.
Issues
- Whether UNAIDS satisfied the requirements under the Judicature (Amicus Curiae) Rules 2022 for admission as amicus curiae.
- Whether the pharmaceutical companies satisfied the requirements under the Judicature (Amicus Curiae) Rules 2022 for admission as amicus curiae.
- Whether the applicants were neutral and impartial, and whether their proposed submissions would assist the Court with novel and useful matters of law.
Orders
- UNAIDS admitted as amicus curiae on conditions.
- UNAIDS to file a brief relating its documented expertise to the dispute before the Court.
- No further documents may be added to those already filed by UNAIDS.
- UNAIDS to file its brief no later than Friday 15th December 2023.
- The application by the pharmaceutical companies to be admitted as amicus curiae is declined.
- Each party to bear its own costs.
Key headnotes
Legislation cited (7)
- Judicature (Amicus Curiae) Rules 2022 (SI 54 of 2022) r.4
- Judicature (Amicus Curiae) Rules 2022 (SI 54 of 2022) r.5
- Judicature (Amicus Curiae) Rules 2022 (SI 54 of 2022) r.6(2)
- Judicature (Amicus Curiae) Rules 2022 (SI 54 of 2022) r.6(3)
- Judicature (Amicus Curiae) Rules 2022 (SI 54 of 2022) r.7
- Judicature (Amicus Curiae) Rules 2022 (SI 54 of 2022) r.8
- Anti-Homosexuality Act, 2023
Cases cited (1)
- In re Prof J. Oloka-Onyango & 8 Ors v Amama Mbabazi & Yoweri Kaguta Museveni (Civil Application No. 2 of 2016)